20.10.2010 • NewsQ3 2010Johnson & Johnson

Plunging J&J Consumer Sales Hurt Results

Johnson & Johnson on Tuesday reported disappointing quarterly revenue as sales of U.S. consumer products plunged 25% following recalls of Tylenol and other consumer brands, driving company shares 2% lower.

Although J&J reported better-than-expected quarterly earnings, analysts said the profit beat was largely due to lower taxes and one-time items.

"There was more of a decline in the consumer business than we had expected and not as strong a showing in the medical device business," Nobel Financial Capital analyst Jan Wald said. The diversified healthcare company earned $3.42 billion, or $1.23 per share, in the third quarter. That compared with $3.35 billion, or $1.20 per share, in the year-earlier quarter.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.